If you'd put $20,000 in this ASX healthcare stock in December 2021, you'd have $257,000 now

In just over 2 years, these shares have gone gangbusters, allowing its investors to forget about the losses made by their other investments.

| More on:
Male Lab Worker Wearing White Coat Recording Test Results On Computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even though you buy every ASX stock full of hope, the harsh reality is that not every investment will make you money.

In fact, one must mentally prepare for the inevitability that some stocks will lose you money.

This is not defeatist or alarmist. It's the truth.

But there is good news.

It's that if you diversify your portfolio competently, there might be a few winners that can balance out the losers.

Those winners can sometimes go further than merely cancel out the losses. They could carry the portfolio to huge gains.

I've spoken to many professional investors over the years, and even they all admit they don't achieve anywhere near a 100% success rate. 

Fund managers would happily accept 6 of their 10 stock picks returning a profit.

So with this in mind, let's take a look at an example of a huge winner that's had the heft to carry many losers:

Revenue coming in, R&D continuing

Back on 3 December 2021, Neuren Pharmaceuticals Ltd (ASX: NEU) shares closed the day at $1.77.

Let's say you bought $20,000 of the healthcare stock on that day.

Since then the company has gone from strength to strength.

First it was the commercial release of its Daybue product, which is still the only approved therapy in the world for Rett Syndrome.

A licensing agreement with Acadia Pharmaceuticals Inc (NASDAQ: ACAD) allows the US giant to manufacture Daybue, in return for royalties paid to Neuren.

So that created a flow of cash coming in for the Australian outfit to work on other drugs.

In the past year, favourable testing and regulatory developments for its NNZ-2591 product has sent the stock price soaring.

In fact, Neuren Pharmaceuticals ended up as the best performer on the S&P/ASX 200 Index (ASX: XJO) in 2023.

How one healthcare stock could cure the ailments of others

Now, back to that $20,000 you invested just over two years ago.

That's now worth a cool $257,062.

Showing you such an example isn't meant to send you scrambling to speculate on overnight winners.

The lesson you should be getting out of this is that a few winners in your portfolio will absolutely obliterate the losses.

On 3 December 2021, no one knew how Neuren shares would have turned out in 2024.

So imagine that, in order to diversify your risk, you also bought nine other stocks for $20,000 each.

Incredibly, in an absolute disaster, those other stocks all sank to $0.

Guess what? Your portfolio is still 29% up.

By the way, even now all five analysts surveyed on CMC Invest rate Neuren shares as a buy.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why BHP, Coronado Global, EBR Systems, and Whitehaven Coal shares are pushing higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

a young woman looks happily at her phone in one hand with a selection of shopping bags in her other hand.
BNPL shares

Up 87% since April, why the Zip share price can keep flying higher into 2026

A leading fund manager expects more outsized gains from Zip shares ahead.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Happy coal miner.
Share Gainers

Up 75% this week, why is this ASX All Ords stock rocketing again today?

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a bountiful session for investors this hump day.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »